A new proof-of-concept study reports evidence that a new testing method has the potential to rapidly identify radiation sickness based on biomarkers measured through a single drop of blood. Scientists at The Ohio State University ...
Jul 15, 2020
0
1
The holiday season is a time for joy and celebration but many Americans admit the endless flurry of activities makes it difficult to eat healthy, exercise, and get adequate rest, according to a new survey from The Ohio State ...
Dec 4, 2023
0
0
A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) shows that preparing older acute myeloid ...
Dec 10, 2012
0
0
Keeping track of blood pressure, cholesterol and blood sugar levels can help identify risk factors for heart disease. However, a national survey by The Ohio State University Wexner Medical Center found that while many adults ...
Feb 7, 2024
0
13
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate ...
Jul 5, 2012
0
0
(Medical Xpress)—New research from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) suggests that it may be the quality ...
Jan 22, 2014
0
0
Primary care providers often are the first to identify and evaluate patients with neurocognitive disorders such as mild cognitive impairment, Alzheimer's and dementia.
Jun 20, 2024
0
15
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination ...
Apr 17, 2023
0
2
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according ...
May 31, 2014
0
0
